Nonalcoholic fatty liver disease: a systematic review.

By M. Rinella. Journal of the American Medical Association (JAMA), 2015

2,167 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/b24a7afd0a94ff7469bdecf2a41c7a4ccdded0d6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Z. Younossi
2. R. Loomba
3. A. Sanyal
4. G. Svegliati-Baroni
5. F. Marra
6. Megan H. Bair-Merritt
7. G. Targher
8. M. Rinella

In Epidemiology

1. Z. Younossi
2. R. Loomba
3. A. Sanyal
4. G. Svegliati-Baroni
5. M. Kudo
6. C. Estes
7. F. Marra
8. H. Razavi

In Hepatology

1. Z. Younossi
2. R. Loomba
3. A. Sanyal
4. G. Svegliati-Baroni
5. M. Kudo
6. A. Cheng
7. C. Estes
8. F. Marra

Citations in the corpus

• Lipotoxicity and the gut-liver axis in NASH pathogenesis. (2018, background): “steatohepatitis (NASH), characterized by hepatocellular damage, inflammation and fibrosis , which is a significant risk factor for the development of cirrhosis and hepatocellular carcinoma [2].”
• Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. (2019, background): “, cirrhosis, its complications and HCC) and extra-hepatic diseases, including chronic kidney disease, CVD, and malignancies [14].”
• Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, background): “The other systemic review of NAFLD recommended biannual imaging screening in cirrhosis patients [176].”
• Hepatocellular carcinoma: a review (2016, background): “Diabetes and nonalcoholic fatty liver disease Sixty percent of patients older than 50 years with diabetes or obesity are thought to have NASH with advanced fibrosis.(30)”
• Gut microbiome based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease (2017, neutral): “Graphical abstract Keywords NASH; cirrhosis; biomarker; microbiome; non-invasive; fatty liver; hepatic steatosis; liver disease; hepatitis INTRODUCTION Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the United States, affecting approximately 80–100 mill”
• Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease (2017, background): “Another important implication of the model is the projected increase in the number of individuals with cirrhosis, especially decompensated cirrhosis due to NASH.”
• Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: Systematic Review and Meta-analysis (2017, methodology): “This quality score consisted of seven questions: (1) representative of the average NAFLD adult in the community (1 point for population-based studies, 0.”